Organisation paid for research Program year 2025 Source: CMS Open Payments

Versiti Wisconsin Inc

Neither a doctor nor a teaching hospital

Research payments

$923,345

201 payments

Through program year 2025, Versiti Wisconsin Inc is reported as receiving $923,345 in research payments, across 201 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $65,696 15
2024 Research $192,694 30
2023 Research $397,017 75
2022 Research $186,759 61
2021 Research $31,240 5
2020 Research $39,368 5
2019 Research $10,570 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $457,003 46 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $238,632 128 payments
  3. Genzyme Corporation $136,268 5 payments
  4. Pfizer Inc. $63,789 3 payments
  5. Bioverativ Therapeutics Inc. $12,673 12 payments
  6. Eli Lilly and Company $9,090 2 payments
  7. Amgen Inc. $5,889 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A $318,779 30 payments
  2. A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of Shp655 (Radamts13) in Sickle Cell Disease at Baseline Health and During Acute Vaso-Occlusive Crisis $128,901 91 payments
  3. A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A $115,941 13 payments
  4. A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) $89,135 29 payments
  5. An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura $71,870 3 payments
  6. A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged = 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX $64,398 2 payments
  7. A Randomized Open Label Active Controlled Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of A Venous Thromboembolic Event $41,514 2 payments
  8. OBS effectiveness of Efanesoctocog alfa prophylaxis on joint health in previously treated HEMOA patients $22,284 3 payments
  9. A Phase 12 Openlabel Adaptive Doseranging Study to Assess the Safety and Tolerability of Sb525 Pf07055480 Recombinant Aav26 Human Factor 8 Gene Therapy in Adult Subjects With Severe Hemophilia A $22,275 1 payment
  10. A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of Shp655 (Radamts13) in Sickle Cell Disease at Baseline Health and During Acute Vaso-Occlusive Crisis $14,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record